Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
40 hedge funds and large institutions have $65.3M invested in Genocea Biosciences, Inc. in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 8 closing their positions.
177% more call options, than puts
Call options by funds: $388K | Put options by funds: $140K
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
13% less funds holding
Funds holding: 46 → 40 (-6)
18% less capital invested
Capital invested by funds: $79.4M → $65.3M (-$14.1M)
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$301K |
| 2 |
CC
Commodore Capital
New York
|
+$296K |
| 3 |
Millennium Management
New York
|
+$180K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$82.5K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$48.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$208K |
| 2 |
Two Sigma Investments
New York
|
-$190K |
| 3 |
DC
Diametric Capital
Boston,
Massachusetts
|
-$164K |
| 4 |
PCM
Prelude Capital Management
New York
|
-$102K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$45K |
GNCA Hedge Fund Activity: Q3 2021 in Review
40 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q3 2021, worth a combined $65.3M — down 18% from $79.4M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of GNCA and 2 opened new positions — a net loss of 6 holders — while 8 trimmed existing stakes and 12 added.
The largest buyer was Point72 Asset Management, adding an estimated $301K. The largest seller was Two Sigma Advisers, cutting an estimated $208K.
- 40 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q3 2021, down from 46 in Q2 2021.
- Funds reported $65.3M of Genocea Biosciences, Inc. stock for Q3 2021, down 18% quarter-over-quarter.
- 2 funds opened new Genocea Biosciences, Inc. positions in Q3 2021 and 8 closed out, a net change of -6 holders.
- The largest Genocea Biosciences, Inc. buyer in Q3 2021 was Point72 Asset Management, an estimated $301K added.
- The largest Genocea Biosciences, Inc. seller in Q3 2021 was Two Sigma Advisers, an estimated $208K sold.
Based on aggregated 13F filings for Q3 2021.